OmniComm Systems Acquires EDC Assets of Logos Technologies
8.4.09
Fort Lauderdale, Florida
OmniComm Systems (Fort Lauderdale, FL) has acquired the EDC assets of UK-based Logos Technologies, who has U.S. headquarters in Arlington, VA. The acquisition will be led by OmniComm's UK subsidiary OmniComm Ltd. and provide the parent company with EDC products that cover all aspects of the Phase I process, including subject recruitment, clinical workflow management, and laboratory samplemanagement.
"We are pleased to add the Logos products and operations to the OmniComm team,” said Cornelis F. Wit,
OmniComm's President and CEO, in a company press release. "We believe that the addition of the Logos Phase I products is of importance for OmniComm Systems, as it will broaden the scope of our integrated eClinical solutions offering. Only a very small number of EDC companies specialize in the Phase I market, therefore this acquisition represents animportant addition to our overall corporate growth strategy."
OmniComm reports that the new Logos products will complement their TrialMaster software, which is primarily used in later stage clinical trials.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
